The number of individual cases identified in EudraVigilance for Pfizer-Biontech is **151,306** (up to 24/04/2021)


### TOTAL ADVERSE REACTIONS FOR PFIZER-BIONTECH (up to 24/04/2021)

<table>
<thead>
<tr>
<th>Number of Individual Cases</th>
<th>Number of Individual Cases received over time</th>
<th>Number of Individual Cases by EEA countries</th>
<th>Number of Individual Cases By Reaction Group</th>
<th>Number of Individual Cases at Risk</th>
</tr>
</thead>
</table>

#### FATAL REACTIONS REPORTED BY REACTION GROUP for PFIZER (up to 24/04/2021):


<table>
<thead>
<tr>
<th>#</th>
<th>Reaction Groups - Reaction SOC (not linked to ID)</th>
<th>FATAL (Death)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Blood and lymphatic system disorders</td>
<td>40</td>
</tr>
<tr>
<td>2</td>
<td>Cardiac disorders</td>
<td>522</td>
</tr>
<tr>
<td>3</td>
<td>Congenital, familial and genetic disorders</td>
<td>3</td>
</tr>
<tr>
<td>4</td>
<td>Ear and labyrinth disorders</td>
<td>3</td>
</tr>
<tr>
<td>5</td>
<td>Endocrine disorders</td>
<td>0</td>
</tr>
<tr>
<td>6</td>
<td>Eye disorders</td>
<td>6</td>
</tr>
<tr>
<td>7</td>
<td>Gastrointestinal disorders</td>
<td>227</td>
</tr>
<tr>
<td>8</td>
<td>General disorders and administration site conditions</td>
<td>1,459</td>
</tr>
<tr>
<td>9</td>
<td>Hepatobiliary disorders</td>
<td>16</td>
</tr>
<tr>
<td>10</td>
<td>Immune system disorders</td>
<td>20</td>
</tr>
<tr>
<td>11</td>
<td>Infections and infestations</td>
<td>527</td>
</tr>
<tr>
<td>12</td>
<td>Injury, poisoning and procedural complications</td>
<td>89</td>
</tr>
<tr>
<td>13</td>
<td>Investigations</td>
<td>168</td>
</tr>
<tr>
<td>14</td>
<td>Metabolism and nutrition disorders</td>
<td>91</td>
</tr>
<tr>
<td>15</td>
<td>Musculoskeletal and connective tissue disorders</td>
<td>47</td>
</tr>
<tr>
<td>16</td>
<td>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</td>
<td>7</td>
</tr>
<tr>
<td>17</td>
<td>Nervous system disorders</td>
<td>425</td>
</tr>
<tr>
<td>18</td>
<td>Pregnancy, puerperium and perinatal conditions</td>
<td>7</td>
</tr>
<tr>
<td>19</td>
<td>Product issues</td>
<td>0</td>
</tr>
<tr>
<td>20</td>
<td>Psychiatric disorders</td>
<td>63</td>
</tr>
<tr>
<td>21</td>
<td>Renal and urinary disorders</td>
<td>66</td>
</tr>
<tr>
<td>22</td>
<td>Reproductive system and breast disorders</td>
<td>1</td>
</tr>
<tr>
<td>23</td>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>523</td>
</tr>
<tr>
<td>24</td>
<td>Skin and subcutaneous tissue disorders</td>
<td>35</td>
</tr>
<tr>
<td>25</td>
<td>Social circumstances</td>
<td>6</td>
</tr>
<tr>
<td>26</td>
<td>Surgical and medical procedures</td>
<td>8</td>
</tr>
<tr>
<td>27</td>
<td>Vascular disorders</td>
<td>165</td>
</tr>
</tbody>
</table>

#### TOTAL FATAL REACTIONS (DEATHS) NOT LINKED TO ID

<table>
<thead>
<tr>
<th>Total deaths</th>
<th>total adverse reactions</th>
<th>% death/reactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>4,524</td>
<td>151,306.00</td>
<td>2.99%</td>
</tr>
</tbody>
</table>

#### TOTAL DEATHS LINKED TO ID

<table>
<thead>
<tr>
<th>Total deaths (linked to ID)</th>
<th>total adverse reactions</th>
<th>ratio death/reactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>669</td>
<td>151,306.00</td>
<td>0.44%</td>
</tr>
</tbody>
</table>